NewsBenzingaHarvard Bioscience eleva la previsión de ventas para el ejercicio fiscal 2026 de $88.281M-$90.012M a $89.147M-$90.877M frente a una estimación de $89.794M Harvard Bioscience eleva la previsión de ventas para el ejercicio fiscal 2026 de $88.281M-$90.012M a $89.147M-$90.877M frente a una estimación de $89.794M Benzinga 2026.11.10 12:04 (GMT+0) Open on Benzinga Other news Cybersecurity AI startup Corma reaches $1B valuation in about 3 months Here’s How Much You Would Have Made Owning Advanced Micro Devices Stock In The Last 15 Years Musk Says Owner Robotaxi Trials May Start in December Grupo Supervielle Q3 EPS $0.05 Misses $0.18 Estimate, Sales $149.304M Miss $252.530M Estimate Brad Gerstner Bets $5 Billion on Anthropic IPO: 'Cornerstone Compounder for a Long Time' NVIDIA Targets Desktop HPC With Four-Spark Developer Kit